Palvella Therapeutics (PVLA) Cash from Operations Growth (1y) (2014 - 2026)
Palvella Therapeutics (PVLA) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 158.60% |
| 10 | Palvella Therapeutics | 1.89 Bn | 1.63 Bn | - | -61.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.05% |
| Dec 31, 2025 | 9.03% |
| Sep 30, 2025 | -188.11% |
| Jun 30, 2025 | -238.86% |
| Mar 31, 2025 | -514.16% |
| Dec 31, 2024 | -126.38% |
| Sep 30, 2024 | 71.80% |
| Jun 30, 2024 | 88.06% |
| Mar 31, 2024 | 89.98% |
| Dec 31, 2023 | 258.10% |
| Sep 30, 2023 | -10.77% |
| Jun 30, 2023 | 13.78% |
| Mar 31, 2023 | 51.44% |
| Dec 31, 2022 | -18.17% |
| Sep 30, 2022 | 39.40% |
| Jun 30, 2022 | -152.09% |
| Mar 31, 2022 | -86.55% |
| Dec 31, 2021 | 18.43% |
| Sep 30, 2021 | -91.33% |
| Jun 30, 2021 | 405.85% |